Schering Targets Mylan Over Vytorin ANDA
Merck & Co. Inc. subsidiary Schering Corp. has ignited the latest round of litigation over its cholesterol drug Vytorin, hitting Mylan Pharmaceuticals Inc. with a patent infringement suit following the rival...To view the full article, register now.
Already a subscriber? Click here to view full article